Coherus Biosciences | CHRS - Betriebsaufwand

Aktienkurs
1.68
Täglich Wechseln
0.03 1.82%
Monatlich
-5.62%
Jährlich
100.98%
Q2 Prognose
1.63




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.48M 113K 2025-12
Amgen USD 5.9B 773M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Fujifilm JPY 767.39B 27.7B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Merck USD 10.16B 558M 2025-12
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xencor USD 81.86M 13.35M 2025-12
Zoetis USD 1.55B 3.85B 2025-12